Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Abrocitinib was efficacious and safe in patients with atopic dermatitis who did and who did not respond to prior treatment with dupilumab.

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease ...

Rescue therapy could include treatment with high ... More than 1,000,000 patients are being treated with Dupixent globally.1 Dupilumab is being jointly developed by Regeneron and Sanofi under ...

BLA accepted for review Dupilumab (Regeneron and Sanofi ... sNDA accepted AVB-114 (Avobis Bio) Stem cell therapy Treatment of perianal fistulas in patients with Crohn disease.